Brief Articles
J ournal of Medicinal Chemistry, 2003, Vol. 46, No. 17 3765
(3) Matyus, P.; Horvath, K. R-Adrenergic Approach in the Medical
Management of Benign Prostatic Hyperplasia. Med. Res. Rev.
1997, 6, 523-535 and references therein.
(4) Kerwin, J . F., J r.; Lancaster, J . R., J r.; Feldman, P. L. Nitric
Oxide: A New Paradigm for Second Messengers. J . Med. Chem.
1995, 38, 4343-4362.
(5) Burnett, M. D. Nitric Oxide Control of Lower Genitourinary
Tract Functions: A Review. Urology 1995, 45, 1071-1083.
(6) Fruttero, R.; Boschi, D.; Di Stilo, A.; Gasco, A. The Furoxan
System as a Useful Tool for Balancing “Hybrids” with Mixed
R1-Antagonist and NO-like Vasodilator Activities. J . Med. Chem.
1995, 38, 4944-4949.
(7) Leonardi, A.; Hieble, J . P.; Guarneri, L.; Naselsky, D. P.; Poggesi,
E.; Sironi, G.; Sulpizio, A. C.; Testa, R. Pharmacological Char-
acterisation of the Uroselective Alpha-1 Antagonist Rec 15/2739
(SB 216469): Role of the Alpha-1 L Adrenoreceptor in Tissue
Selectivity, Part I. J . Pharmacol. Exp. Ther. 1997, 81, 1272-
1283.
(8) Sorba, G.; Medana, C.; Fruttero, R.; Cena, C.; Di Stilo, A.; Galli,
U.; Gasco, A. Water Soluble Furoxan Derivatives as NO Pro-
drugs. J . Med. Chem. 1997, 40, 463-469 and references therein;
1997, 40, 2288.
(9) Feelisch, M., Stamler, J . S., Eds. Methods in Nitric Oxide
Research; J ohn Wiley & Sons: Chichester, U.K., 1996.
(10) Testa, R.; Guarneri, L.; Poggesi, E.; Angelico, P.; Velasco, C.;
Ibba, M.; Cilia, A.; Motta, G.; Riva, C.; Leonardi, A. Effect of
Several 5-Hydroxytryptamine1A Receptor Ligands on the Mic-
turition Reflex in Rats: Comparison with WAY 100635. J .
Pharmacol. Exp. Ther. 1999, 290, 1258-1269.
(11) Bolognesi, M. L.; Budriesi, R.; Cavalli, A.; Chiarini, A.; Gotti,
R.; Leonardi, A.; Minarini, A.; Poggesi, E.; Recanatini, M.; Rosini,
M.; Tumiatti, V.; Melchiorre, C. WB 4101-Related Compounds.
2. Role of the Ethylene Chain Separating Amine and Phenoxy
Units on the Affinity for R1-Adrenoceptor Subtypes and 5-HT1A
Receptors. J . Med. Chem. 1999, 42, 4214-4224.
(12) Testa, R.; Guarnieri, L.; Taddei, C.; Poggesi, E.; Angelico, P.;
Sartani, A.; Leonardi, A.; Gofrit, O. N.; Meretyk, S.; Caine, M.
Functional Antagonistic Activity of Rec 15/2739, a Novel Alpha-1
Antagonist Selectivity for the Lower Urinary Tract, on Norad-
renaline-Induced Contraction of Human Prostate and Mesenteric
Artery. J . Pharmacol. Exp. Ther. 1996, 277, 1237-1246.
(13) Quaglia, W.; Pigini M.; Piergentili, A.; Giannella, M.; Gentili,
F.; Marucci, G.; Carrieri, A.; Carotti, A.; Poggesi, E.; Leonardi,
A.; Melchiorre, C. Stucture-activity Relationships in 1,4-Ben-
zodioxan-Related Compounds. 7. Selectivity of 4-Phenylchroman
Analogues for R1-Adrenoceptor Subtypes. J . Med. Chem 2002,
45, 1633-1643.
g (57%) of the product as a pale-yellow solid: mp 77 °C (dec).
Anal. (C34H32N6O6‚0.5H2O) C, H, N.
N-(3-(4-(2-(3-Br om op r op oxy)p h en yl)p ip er a zin -1-yl)-
p r op yl)-3-m eth yl-4-oxo-2-p h en yl-4H-ch r om en e-8-ca r box-
a m id e (9). 1,3-Dibromopropane (8, 0.49 mL, 4,80 mmol) and
6 N NaOH (0.80 mL, 4,80 mmol) were added to a stirred
solution of 2 (1.20 g, 2.40 mmol) in THF (15 mL). The solution
was heated at 45 °C until the disappearance of starting
material by TLC (24 h). The solution was then diluted with
EtOAc, washed with water and brine, and then dried and
evaporated. The crude material, purified by column chroma-
tography (eluent, EtOAc/PE/7 N NH3 in MeOH, 6:3.5:0.5), gave
0.80 g (54%) of the product as white powder that was
crystallized from ethanol and dried at 40 °C under vacuum
for 3 days: mp (EtOH) 131-133 °C. Anal. (C33H36BrN3O4‚
0.25H2O) C, H, N.
N-(3-(4-(2-(3-Nitr ooxyp r op oxy)p h en yl)p ip er a zin -1-yl)-
p r op yl)-3-m eth yl-4-oxo-2-p h en yl-4H-ch r om en e-8-ca r box-
a m id e (10). To a suspension of 9 (0.62 g, 1.00 mmol) in
acetonitrile (10 mL), silver nitrate (0.34 g, 2.00 mmol) was
added, and the reaction mixture was refluxed for 4 h. The
silver bromine formed was filtered off, and the solvent was
carefully evaporated. The residue was taken up in EtOAc,
washed with water and brine, and then dried and evaporated.
The crude residue was purified by column chromatography
(eluent, EtOAc/PE/7 N NH3 in MeOH, 6:3.5:0.5) and afforded
0.25 g (41%) of a pale-yellow solid that was further purified
by two crystallizations with 95% EtOH: mp (EtOH) 139-142
°C (dec). Anal. (C33H36N4O7) C, H, N.
Ack n ow led gm en t. Financial support from the Ital-
ian MIUR is gratefully acknowledged.
Su p p or tin g In for m a tion Ava ila ble: Detailed experi-
mental procedures on the radioligand binding assays and
functional studies of compounds 1, 5-7, and 10, including a
description of the standard techniques and instrument used
for the synthesis of the compounds, and their NMR data. This
material is available free of charge via the Internet at http://
pubs.acs.org.
(14) Miyamoto, Y.; Noguchi, K.; Nakasone, J .; Sakanashi, M. Phar-
macological Properties of 5-[(6,7,8-Trimethoxy-4-quinazolinyl)-
amino]-1-pentanyl Nitrate Maleate in Cardiovascular System.
Arzneim.-Forsch. 1991, 41, 1216-1221.
Refer en ces
(1) Caine, M.; Perlberg, S. Dynamics of Acute Retention in Prostatic
Patients and Role of Adrenergic receptors. Urology 1977, 9, 399-
403.
(2) Zhong, H.; Minneman, K. P. Alpha1-Adrenoceptor Subtypes. Eur.
J . Pharmacol. 1999, 375, 261-276.
J M030825U